Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE versus NORMIFLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE versus NORMIFLO.
ATROPINE vs NORMIFLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists. Inhibits vagal activity, increases heart rate, reduces secretions, and relaxes smooth muscle.
NORMIFLO is a selective alpha-1 adrenergic receptor antagonist that inhibits the binding of norepinephrine to alpha-1 receptors in the smooth muscle of the prostate and bladder neck, leading to relaxation of these muscles and improved urine flow.
0.5-1 mg IV/IM/SC every 3-5 minutes as needed, up to a total of 3 mg (adults). For preoperative use, 0.4-0.6 mg IM/IV 30-60 minutes before anesthesia.
Adults: 75 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateBenzatropine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Benzatropine."
Clinical Note
moderateBenzatropine + Dronedarone
2-4 hours (terminal); prolonged in elderly and neonates; clinically requires dosing every 4-6 hours
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (30-50% unchanged; remainder as inactive metabolites via hydrolysis and glucuronidation); 50-70% of a dose renally excreted as metabolites; <5% fecal
Renal excretion of unchanged drug accounts for 65-75% of elimination; biliary/fecal excretion accounts for 20-30%, with the remainder as metabolites.
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent
"The metabolism of Dronedarone can be decreased when combined with Benzatropine."